A Phase 1 study of Humalutin, a chimeric anti-CD37 Antibody Radionuclide Conjugate (ARC) in Non-Hodgkin's-lymphoma.

Trial Profile

A Phase 1 study of Humalutin, a chimeric anti-CD37 Antibody Radionuclide Conjugate (ARC) in Non-Hodgkin's-lymphoma.

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Chimeric-anti-CD37-Antibody-Radionuclide-Conjugate (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 New trial record
    • 24 May 2017 According to a Nordic Nanovector media release, the trial is expected to begin in 2H 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top